AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30201039 — intervention group
Group type: EXPERIMENTAL
Intervention: E-WORTH intervention combined with streamlined HIV testing
Number of subjects: 0
Study 30201039 — intervention group
Group type: COMPARATOR
Intervention: Streamlined HIV testing alone
Number of subjects: 0
Study 27269946 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Number of subjects: 521
Study 27269946 — intervention group
Group type: COMPARATOR
Intervention: Exemestane
Number of subjects: 521
Study 27269946 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant plus palbociclib
Number of subjects: 521
Study 27269946 — intervention group
Group type: COMPARATOR
Intervention: Fulvestrant plus placebo
Number of subjects: 521
Study 24899464 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 38
Study 24899464 — intervention group
Group type: COMPARATOR
Intervention: Why WAIT (intensive diabetes medical and weight management program)
Number of subjects: 38
Study 22329987 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term energy surfeit treatment (BOOST®)
Number of subjects: 0
Study 22329987 — intervention group
Group type: COMPARATOR
Intervention: Short-term post-absorptive state (water only)
Number of subjects: 0
Study 21094429 — intervention group
Group type: EXPERIMENTAL
Intervention: Resource communication
Number of subjects: 534
Study 21094429 — intervention group
Group type: EXPERIMENTAL
Intervention: Planning
Number of subjects: 534
Study 21094429 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 534
Study 22126936 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C
Number of subjects: 16401
Study 22126936 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD-EPI
Number of subjects: 16401
Study 15939317 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 mcg
Number of subjects: 51
Study 15939317 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 800 mcg
Number of subjects: 51
Study 15939317 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 51
Study 12459618 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental mouthrinse containing propolis SNB‐RS
Number of subjects: 6
Study 12459618 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 6
Study 10483896 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine-enriched enteral nutrition
Number of subjects: 0
Study 10483896 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard enteral nutrition)
Number of subjects: 0
Study 8733890 — intervention group
Group type: EXPERIMENTAL
Intervention: Erucic acid (component of Lorenzo's oil)
Number of subjects: 39
Study 8733890 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 39
Study 1660825 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of conjugated oestrogen, dosage not specified, duration not specified.
Number of subjects: 0
Study 1660825 — intervention group
Group type: COMPARATOR
Intervention: Atropine sulphate, dosage not specified, duration not specified.
Number of subjects: 0
Study 7041323 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipuncture BCG (50 to 250 X 10(6) viable units)
Number of subjects: 92
Study 7041323 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal BCG (0.4 to 0.9 X 10(6) viable units)
Number of subjects: 92
Study 7041323 — intervention group
Group type: COMPARATOR
Intervention: Control group (no BCG immunotherapy)
Number of subjects: 92
Study 29730966 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative learning activity using virtual patients (VPs)
Number of subjects: 158
Study 29730966 — intervention group
Group type: COMPARATOR
Intervention: Independent learning activity using virtual patients (VPs)
Number of subjects: 158
Study 27633286 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS stimulation (10 sessions, 20 trains of 5 seconds at 10 Hz)
Number of subjects: 47
Study 27633286 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (control group)
Number of subjects: 47
Study 25557828 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg
Number of subjects: 302
Study 25557828 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg
Number of subjects: 302
Study 25557828 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19*2 loss‐of‐function (LOF) carriers
Number of subjects: 302
Study 25557828 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-carriers
Number of subjects: 302
Study 25557828 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain of function carriers
Number of subjects: 302
Study 23645178 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP)
Number of subjects: 50
Study 23645178 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential-oils mouthwash
Number of subjects: 50
Study 20543727 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.37-kg overweight implement (OVRWGHT1)
Number of subjects: 10
Study 20543727 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.27-kg overweight implement (OVRWGHT2)
Number of subjects: 10
Study 20543727 — intervention group
Group type: COMPARATOR
Intervention: Regulation weight (STAND)
Number of subjects: 10
Study 18271706 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone-ER
Number of subjects: 0
Study 18271706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15855885 — intervention group
Group type: EXPERIMENTAL
Intervention: Domestic ELF-EMF exposure above the upper tertile at low current configuration
Number of subjects: 51
Study 15855885 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily alcohol intake
Number of subjects: 51
Study 15855885 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) above the median
Number of subjects: 51
Study 12952836 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP-3
Number of subjects: 25
Study 12952836 — intervention group
Group type: EXPERIMENTAL
Intervention: MMP-9
Number of subjects: 25
Study 12952836 — intervention group
Group type: COMPARATOR
Intervention: MMP-2
Number of subjects: 25
Study 10928520 — intervention group
Group type: EXPERIMENTAL
Intervention: Reteplase for arterial occlusions
Number of subjects: 37
Study 10928520 — intervention group
Group type: EXPERIMENTAL
Intervention: Reteplase for venous occlusions
Number of subjects: 37
Study 8905028 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-weekly chemotherapy (cyclophosphamide 600 mg/m2, carboplatin 300 mg/m2, doxorubicin 50 mg/m2, ifosfamide 5 g/m2)
Number of subjects: 144
Study 8905028 — intervention group
Group type: COMPARATOR
Intervention: Four-weekly chemotherapy (cyclophosphamide 600 mg/m2, carboplatin 300 mg/m2, doxorubicin 50 mg/m2, ifosfamide 5 g/m2)
Number of subjects: 144
Study 1756257 — intervention group
Group type: EXPERIMENTAL
Intervention: Ki-67 positivity (group III)
Number of subjects: 568
Study 1756257 — intervention group
Group type: EXPERIMENTAL
Intervention: Ki-67 reactivity
Number of subjects: 568
Study 1756257 — intervention group
Group type: COMPARATOR
Intervention: Ki-67 groups I and II
Number of subjects: 568
Study 1756257 — intervention group
Group type: COMPARATOR
Intervention: Ki-67 groups II and III
Number of subjects: 568
Study 1756257 — intervention group
Group type: EXPERIMENTAL
Intervention: pT2 and G-II carcinomas
Number of subjects: 568
Study 6802691 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCZ) 50 mg once daily (or 50 mg twice a day for 2 patients)
Number of subjects: 32
Study 6802691 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCZ) plus Nadolol (40 mg to 240 mg once daily)
Number of subjects: 32
Study 6802691 — intervention group
Group type: COMPARATOR
Intervention: Nadolol (40 mg to 240 mg once daily)
Number of subjects: 32
Study 29562396 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency treatment with ultrasound guidance
Number of subjects: 128
Study 26935509 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic Walking (NW) technique
Number of subjects: 24
Study 26935509 — intervention group
Group type: COMPARATOR
Intervention: Walking without NW poles
Number of subjects: 24
Study 24221577 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiated organic manuka honey (5 ml, four times a day during radiation treatment plus seven days)
Number of subjects: 81
Study 24221577 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel (5 ml, four times a day during radiation treatment plus seven days)
Number of subjects: 81
Study 22819187 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiation of recombinant FSH/GnRH antagonist/recombinant LH/hCG on day 1 (n = 39)
Number of subjects: 80
Study 22819187 — intervention group
Group type: COMPARATOR
Intervention: Initiation of recombinant FSH/GnRH antagonist/recombinant LH/hCG on day 4 (n = 41)
Number of subjects: 80
Study 22819187 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 1 group
Number of subjects: 80
Study 20546568 — intervention group
Group type: EXPERIMENTAL
Intervention: Worksite prevention program consisting of two individual training sessions by a physical therapist, a Rest-Break tool, and two empowerment training sessions.
Number of subjects: 0
Study 20546568 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 18669713 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritgen's maneuver
Number of subjects: 1423
Study 18669713 — intervention group
Group type: COMPARATOR
Intervention: Simple perineal support
Number of subjects: 1423
Study 16355621 — intervention group
Group type: EXPERIMENTAL
Intervention: Huoxue Jieyu decoction (HJD)
Number of subjects: 90
Study 16355621 — intervention group
Group type: COMPARATOR
Intervention: Chlorimipramine (anafranil)
Number of subjects: 90
Study 11985944 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.35 g/kg of fat-free mass)
Number of subjects: 20
Study 11985944 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 20
Study 10215716 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital palpation technique after training
Number of subjects: 20
Study 10215716 — intervention group
Group type: COMPARATOR
Intervention: Reusable laryngeal mask airway
Number of subjects: 20
Study 10215716 — intervention group
Group type: COMPARATOR
Intervention: Disposable laryngeal mask airway
Number of subjects: 20
Study 10215716 — intervention group
Group type: EXPERIMENTAL
Intervention: Low initial pressure
Number of subjects: 20
Study 10215716 — intervention group
Group type: EXPERIMENTAL
Intervention: High initial pressure
Number of subjects: 20
Study 10215716 — intervention group
Group type: COMPARATOR
Intervention: Pre-training phase
Number of subjects: 20
Study 8536758 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and cisplatin (135 mg/m2 or 175 mg/m2 of paclitaxel and 50 mg/m2, 75 mg/m2, or 100 mg/m2 of cisplatin)
Number of subjects: 15
Study 8536758 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and cisplatin
Number of subjects: 15
Study 2195035 — intervention group
Group type: EXPERIMENTAL
Intervention: Double latex gloves (Group I)
Number of subjects: 50
Study 2195035 — intervention group
Group type: COMPARATOR
Intervention: Cloth outer gloves with latex inner gloves (Group II)
Number of subjects: 50
Study 343907 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC + cyclophosphamide
Number of subjects: 101
Study 343907 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC + vinblastine
Number of subjects: 101
Study 343907 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC + procarbazine
Number of subjects: 101
Study 343907 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 101
Study 31944826 — intervention group
Group type: EXPERIMENTAL
Intervention: RADAR system ablation
Number of subjects: 64
Study 31640994 — intervention group
Group type: EXPERIMENTAL
Intervention: TiM plus usual care
Number of subjects: 40
Study 31640994 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 40
Study 28228504 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat emulsion structure (4 different emulsions)
Number of subjects: 17
Study 25592751 — intervention group
Group type: EXPERIMENTAL
Intervention: 14.5 g spices (black pepper, cinnamon, cloves, garlic, ginger, oregano, paprika, rosemary, and turmeric)
Number of subjects: 20
Study 25592751 — intervention group
Group type: COMPARATOR
Intervention: Placebo (low spice meal)
Number of subjects: 20
Study 25592751 — intervention group
Group type: EXPERIMENTAL
Intervention: Spice blend and individual spices (in vitro)
Number of subjects: 20
Study 24151277 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (ALN) administration (35 mg once weekly for six months)
Number of subjects: 80
Study 24151277 — intervention group
Group type: COMPARATOR
Intervention: Delayed ALN administration (not specified dosage, started four months after surgery)
Number of subjects: 80
Study 24151277 — intervention group
Group type: COMPARATOR
Intervention: Both groups (ALN and no-ALN)
Number of subjects: 80
Study 22076970 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (CBGT)
Number of subjects: 45
Study 22076970 — intervention group
Group type: COMPARATOR
Intervention: Group psychotherapy (GPT)
Number of subjects: 45
Study 19363053 — intervention group
Group type: EXPERIMENTAL
Intervention: OptiSense 1699T lead
Number of subjects: 63
Study 19363053 — intervention group
Group type: COMPARATOR
Intervention: Conventional pacing lead
Number of subjects: 63
Study 17942873 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 551
Study 17942873 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 551
Study 17942873 — intervention group
Group type: EXPERIMENTAL
Intervention: Both prednisolone and acyclovir
Number of subjects: 551
Study 17942873 — intervention group
Group type: COMPARATOR
Intervention: No prednisolone
Number of subjects: 551
Study 17942873 — intervention group
Group type: COMPARATOR
Intervention: No acyclovir
Number of subjects: 551
Study 15284267 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life measures (HRQL) including Short Form-36 (SF-36) for ages > 13 years and Child Health Questionnaire-Child Form 87 (CHQ-CF87) for ages <= 13 years
Number of subjects: 127
Study 15284267 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal cardiac index (MCI)
Number of subjects: 127
Study 11527909 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ferric hyaluronate gel
Number of subjects: 77
Study 11527909 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 77
Study 9428861 — intervention group
Group type: EXPERIMENTAL
Intervention: D-myo-inositol-1,2,6-trisphosphate (1,2,6-IP3) intravenous bolus dose of 240 mg followed by continuous infusion at 90 mg/h for 24 h
Number of subjects: 24
Study 9428861 — intervention group
Group type: EXPERIMENTAL
Intervention: D-myo-inositol-1,2,6-trisphosphate (1,2,6-IP3)
Number of subjects: 24
Study 9428861 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 24
Study 7641722 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil 30 micrograms kg‐1
Number of subjects: 30
Study 7641722 — intervention group
Group type: EXPERIMENTAL
Intervention: ketamine 1.5 mg kg‐1
Number of subjects: 30
Study 7641722 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride (control)
Number of subjects: 30
Study 2621178 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir, 800 mg tid
Number of subjects: 5
Study 1251139 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis replacement therapy with biweekly administration of 7.5 U/kg of factor IX concentrate
Number of subjects: 10
Study 1251139 — intervention group
Group type: COMPARATOR
Intervention: Prophylaxis replacement therapy with weekly administration of 15 U/kg of factor IX concentrate
Number of subjects: 10
Study 1251139 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis replacement therapy (both schemes)
Number of subjects: 10
Study 31448433 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib (1 mg to 48 mg)
Number of subjects: 0
Study 31448433 — intervention group
Group type: COMPARATOR
Intervention: Tofacitinib (5 mg BID)
Number of subjects: 0
Study 31448433 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib (∼12 mg BID)
Number of subjects: 0
Study 31221115 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation (Pre-CRT) - two cycles of S-1 and oxaliplatin (SOX), followed by chemoradiation, then surgery and three more cycles of SOX chemotherapy.
Number of subjects: 0
Study 31221115 — intervention group
Group type: COMPARATOR
Intervention: Preoperative chemotherapy (Pre-CT) - three cycles of SOX, followed by surgery and three more cycles of SOX chemotherapy.
Number of subjects: 0
Study 28646390 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser + topical drug (calcipotriol ointment)
Number of subjects: 5
Study 28646390 — intervention group
Group type: COMPARATOR
Intervention: Drug alone (calcipotriol ointment)
Number of subjects: 5
Study 26057652 — intervention group
Group type: EXPERIMENTAL
Intervention: Cincinnati Prehospital Stroke Scale (CPSS)
Number of subjects: 246
Study 26057652 — intervention group
Group type: COMPARATOR
Intervention: National Guidelines for Telephone Triage Tool (NGTT)
Number of subjects: 246
Study 22976882 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct memory test (recognition)
Number of subjects: 0
Study 22976882 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect memory test (identification)
Number of subjects: 0
Study 21640878 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash
Number of subjects: 160
Study 21640878 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral B mouthwash
Number of subjects: 160
Study 21640878 — intervention group
Group type: EXPERIMENTAL
Intervention: Persica mouthwash
Number of subjects: 160
Study 21640878 — intervention group
Group type: COMPARATOR
Intervention: Distilled deionized water
Number of subjects: 160
Study 21640878 — intervention group
Group type: EXPERIMENTAL
Intervention: All mouthwashes (Chlorhexidine, Oral B, Persica)
Number of subjects: 160
Study 19373095 — intervention group
Group type: EXPERIMENTAL
Intervention: EasyTube (EZT)
Number of subjects: 88
Study 19373095 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway (PLMA)
Number of subjects: 88
Study 19373095 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal tube S II (LTS II)
Number of subjects: 88
Study 19373095 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotracheal tube
Number of subjects: 88
Study 16769002 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical surgery (ligature and section at the sapheno-femoral junction and collateral veins, with saphenectomy)
Number of subjects: 100
Study 16769002 — intervention group
Group type: COMPARATOR
Intervention: 3-S saphenectomy technique (sclerosis injection at the sapheno-femoral junction with microfoam through a catheter, with saphenectomy and distal phlebectomies)
Number of subjects: 100
Study 16769002 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical surgery
Number of subjects: 100
Study 16769002 — intervention group
Group type: COMPARATOR
Intervention: 3-S saphenectomy technique
Number of subjects: 100
Study 12685950 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertomic saline enema
Number of subjects: 45
Study 12685950 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscinbutylbromide in infusion
Number of subjects: 45
Study 12685950 — intervention group
Group type: COMPARATOR
Intervention: I/V fluids only
Number of subjects: 45
Study 10606475 — intervention group
Group type: EXPERIMENTAL
Intervention: HBO‐4 (hyperbaric oxygen at 4 atmospheres)
Number of subjects: 48
Study 10606475 — intervention group
Group type: COMPARATOR
Intervention: Air (control group)
Number of subjects: 48
Study 8596107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 1753422 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of norfloxacin (chemoprophylaxis)
Number of subjects: 20
Study 1753422 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (without any antimicrobials except when overt UTI occurred)
Number of subjects: 20
Study 6760378 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of azathioprine
Number of subjects: 154
Study 6760378 — intervention group
Group type: COMPARATOR
Intervention: 10-15 mg of prednisone daily
Number of subjects: 154
Study 3882107 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous BRL 26921
Number of subjects: 16
Study 3882107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30442864 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based kidney care program
Number of subjects: 98
Study 30442864 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 98
Study 26795566 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 25
Study 26795566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 25083759 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS over DLPFC
Number of subjects: 21
Study 25083759 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS over primary motor cortex
Number of subjects: 21
Study 25083759 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 21
Study 22860481 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert role modeling video
Number of subjects: 275
Study 22860481 — intervention group
Group type: COMPARATOR
Intervention: Control group (no expert role modeling video)
Number of subjects: 275
Study 20237060 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-enriched diet
Number of subjects: 13
Study 20237060 — intervention group
Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 13
Study 18341601 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD/SBC (Enamel Matrix Derivative/Synthetic Bone Graft)
Number of subjects: 73
Study 18341601 — intervention group
Group type: COMPARATOR
Intervention: EMD (Enamel Matrix Derivative)
Number of subjects: 73
Study 15712339 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncertainty management intervention delivered during four weekly telephone sessions with cognitive-behavioral strategies and a self-help manual.
Number of subjects: 509
Study 15712339 — intervention group
Group type: COMPARATOR
Intervention: Usual care control condition.
Number of subjects: 509
Study 14717307 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective Caesarean delivery
Number of subjects: 0
Study 14717307 — intervention group
Group type: COMPARATOR
Intervention: Vaginal birth
Number of subjects: 0